Correspondence 0001493152-23-018977 from CancerVAX, Inc. (CIK 0001905495)
CancerVAX, Inc. (CIK 0001905495)
Date: May 24, 2023 · CIK: 0001905495 · Accession: 0001493152-23-018977
AI Filing Summary & Sentiment
File numbers found in text: 024-12130
Letter
Re: CancerVAX, Inc.
May 24, 2023
Via EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
F Street, N.E.
Washington, DC 20549
Offering Statement on Form 1-A/A
Filed April 26, 2023
File No. 024-12130
Ladies and Gentlemen:
On behalf of CANCERVAX, INC. (the “Company”), I hereby request qualification of the Company’s above referenced Offering Statement at 12:00 pm Eastern Time, on Tuesday, May 30, 2023, or as soon thereafter as is practicable.
Very
truly yours,
CANCERVAX,
INC.
Show Raw Text
CORRESP
1
filename1.htm
May
24, 2023
Via
EDGAR
United
States Securities and Exchange Commission
Division
of Corporation Finance
Office
of Life Sciences
100
F Street, N.E.
Washington,
DC 20549
Re:
CancerVAX,
Inc.
Offering
Statement on Form 1-A/A
Filed
April 26, 2023
File
No. 024-12130
Ladies
and Gentlemen:
On
behalf of CANCERVAX, INC. (the “Company”), I hereby request qualification of the Company’s above referenced Offering
Statement at 12:00 pm Eastern Time, on Tuesday, May 30, 2023, or as soon thereafter as is practicable.
Very
truly yours,
CANCERVAX,
INC.
/s/
Ryan Davies
Ryan
Davies, CEO